文献速递胸部肿瘤

荷兰转移性非小细胞肺癌患者预测性生物标志物检测率的地区差异

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
PubMed 文献 · Eur J Cancer · 2024-05-20

该研究整合荷兰癌症登记处临床数据与荷兰全国病理数据库病理报告,分析2019年荷兰全部3877例转移性非鳞状非小细胞肺癌患者的预测性生物标志物检测率。结果显示非融合驱动基因检测率为73.9%至89.0%,融合驱动基因检测率为12.6%至63.9%,EGFR、KRAS和ALK指南依从性检测率为85.2%,地区间从76.0%至90.8%不等。结论认为需要优化荷兰NSCLC患者预测性生物标志物检测的诊疗链。

要点

  • 2019年荷兰3877例转移性非鳞状NSCLC中,非融合驱动基因检测率为73.9%至89.0%。
  • 融合驱动基因(ALK、ROS1、RET、NTRK)检测率为12.6%至63.9%。
  • EGFR、KRAS和ALK指南依从性检测率为85.2%,地区间从76.0%至90.8%不等。

核心结论

  • 需要优化荷兰非小细胞肺癌患者预测性生物标志物检测的诊疗链,以为这些患者提供充分的医疗照护。

研究设计与样本

  • 研究整合荷兰癌症登记处临床数据与荷兰全国病理数据库病理报告,纳入2019年荷兰全部3877例转移性非鳞状非小细胞肺癌患者。
  • 从病理报告提取的数据包括样本类型、诊断及预测性生物标志物的分子检测状态。

主要发现

  • 在3877例转移性非鳞状非小细胞肺癌患者中,非融合预测性生物标志物(EGFR、KRAS、BRAF、ERBB2、MET)的总体分子检测率为73.9%至89.0%。
  • 融合驱动基因(ALK、ROS1、RET、NTRK)的分子检测率为12.6%至63.9%。
  • EGFR、KRAS和ALK的指南依从性检测在85.2%的患者中完成,地区检测率从76.0%至90.8%不等。
  • 与指南依从性生物标志物检测相关的人口学和临床因素包括较低年龄(每降低1岁,OR=1.05;p<0.001)、女性(OR=1.36;p=0.002)、腺癌诊断(OR=2.48;p<0.001)、可获得组织学肿瘤材料(OR=2.46;p<0.001)及转移性疾病临床分期(p=0.002)。
  • 其他与指南依从性生物标志物检测相关的因素包括在学术中心诊断(OR=1.87;p=0.002)和患者居住地区(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predictive biomarker testing has a key role in the treatment decision-making for patients with non-small cell lung cancer (NSCLC) and is mandated by (inter)national guidelines. The aim of this study was to establish guideline-adherent biomarker testing rates in the Netherlands in 2019 and to examine associations of demographical, clinical, and environmental factors with guideline-adherent testing. METHODS: This study involved the integration of clinical data of the Netherlands Cancer Registry with pathology reports of the Dutch Nationwide Pathology Databank. Data extracted from these reports included sample type, diagnosis, and molecular testing status of predictive biomarkers. The study population comprised all patients diagnosed with metastatic non-squamous NSCLC in the Netherlands in 2019. RESULTS: In the cohort of 3877 patients with metastatic non-squamous NSCLC under investigation, overall molecular testing rates for non-fusion predictive biomarkers (EGFR, KRAS, BRAF, ERBB2, MET) ranged from 73.9 to 89.0 %, while molecular testing for fusion-drivers (ALK, ROS1, RET, NTRK) ranged from 12.6 % to 63.9 %. Guideline-adherent testing of EGFR, KRAS, and ALK was performed in 85.2 % of patients, with regional rates spanning from 76.0 % to 90.8 %. Demographical and clinical factors associated with guideline-adherent biomarker testing included lower age (OR = 1.05 per one year decrease; p < 0.001), female sex (OR = 1.36; p = 0.002), diagnosis of adenocarcinoma (OR = 2.48; p < 0.001), availability of histological tumor material (OR = 2.46; p < 0.001), and clinical stage of metastatic disease (p = 0.002). Other factors associated with guideline-adherent biomarker testing included diagnosis at academic center (OR = 1.87; p = 0.002) and patient's region of residence (p < 0∙001). CONCLUSION: Optimization of the chain-of-care of predictive biomarker testing in patients with NSCLC in the Netherlands is needed to provide adequate care for these patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. de Jager VD, Cajiao Garcia BN, Kuijpers CCHJ, et al. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands. Eur J Cancer. 2024. PMID: 38788285. doi:10.1016/j.ejca.2024.114125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。